PTEN protein expression in malignant pleural mesothelioma

Tumor Biology

Volumn 34, Issue 2, 2013, Pages 847-851

  Agarwal, Vijay ^a,b,c   Campbell, Anne ^a,c   Beaumont, Kate L ^a   Cawkwell, Lynn ^a,b   Lind, Michael J ^a,b,c  

^a UNIVERSITY OF HULL   (United Kingdom)

^b CASTLE HILL HOSPITAL   (United Kingdom)

^c HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

AKT; Immunohistochemistry; Mesothelioma; MTOR pathway; PTEN

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PTEN PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MESOTHELIUM CELL; PATIENT SELECTION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; ENZYME IMMUNOASSAY; FOLLOW UP; MESOTHELIOMA; METABOLISM; MORTALITY; NEOPLASM; PATHOLOGY; PLEURA TUMOR; PROGNOSIS; SURVIVAL RATE;

FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MESOTHELIOMA; NEOPLASMS, GLANDULAR AND EPITHELIAL; PLEURAL NEOPLASMS; PROGNOSIS; PTEN PHOSPHOHYDROLASE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84877128180     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0615-9     Document Type: Article

References (38)

1. Rake C, Gilham C, Hatch J, Darnton A, Hodgson J, Peto J. Occupational, domestic and environmental mesothelioma risks in the british population: a case-control study. Br J Cancer. 2009;100:1175-83.
2. Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med. 1992;34:718-21.
3. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol. 2002;29:2-17.
4. Tan E, Warren N, Darnton AJ, Hodgson JT. Projection of mesothelioma mortality in Britain using Bayesian methods. Br J Cancer. 2010;103:430-6.
5. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The european mesothelioma epidemic. Br J Cancer. 1999;79:666-72.
6. Stahel RA, Weder W, Felip E. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:73-5.
7. Grosso F, Scagliotti GV. Systemic treatment of malignant pleural mesothelioma. Future Oncol. 2012;8:293-305.
8. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-44.
9. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the european organisation for research and treatment of cancer lung cancer group and the national cancer institute of canada. J Clin Oncol. 2005;23:6881-9.
10. van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P. Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol. 2010;78(2):92-111.
11. Ceresoli GL, Locati LD, Ferreri AJ, Cozzarini C, Passoni P, Melloni G, et al. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer. 2001;34:279-87.
12. O'Kane SL, Cawkwell L, Campbell A, Lind MJ. Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma. Eur J Cancer. 2005;41:1645-8.
13. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, mmac1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356-62.
14. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. Pten, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943-7.
15. Li DM, Sun H. Tep1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 1997;57:2124-9.
16. Ali IU, Schriml LM, Dean M. Mutational spectra of pten/mmac1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst. 1999;91:1922-32.
17. Kohno T, Takahashi M, Manda R, Yokota J. Inactivation of the pten/mmac1/tep1 gene in human lung cancers. Genes Chromosome Cancer. 1998;22:152-6.
18. Wang SI, Parsons R, Ittmann M. Homozygous deletion of the pten tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res. 1998;4:811-5.
19. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, et al. Interfocal heterogeneity of pten/mmac1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 1998;58:204-9.
20. Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM. Analysis of pten and the 10q23 region in primary prostate carcinomas. Oncogene. 1998;16:1743-8.
21. Bostrom J, Cobbers JM, Wolter M, Tabatabai G, Weber RG, Lichter P, et al. Mutation of the pten (mmac1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res. 1998;58:29-33.
22. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, et al. Mutations in pten are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997;57:3935-40.
23. Risinger JI, Hayes AK, Berchuck A, Barrett JC. Pten/mmac1 mutations in endometrial cancers. Cancer Res. 1997;57:4736-8.
24. Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J. Mutation analysis of the putative tumor suppressor gene pten/mmac1 in primary breast carcinomas. Cancer Res. 1997;57:3657-9.
25. Nelen MR, van Staveren WC, Peeters EA, Hassel MB, Gorlin RJ, Hamm H, et al. Germline mutations in the pten/mmac1 gene in patients with Cowden disease. Hum Mol Genet. 1997;6:1383-7.
26. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al. Germline mutations of the pten gene in cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16:64-7.
27. Hollander MC, Blumenthal GM, Dennis PA. Pten loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 2011;11:289-301.
28. Maehama T, Dixon JE. The tumor suppressor, pten/mmac1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273:13375-8.
29. Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, et al. Human and mouse mesotheliomas exhibit elevated akt/pkb activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene. 2005;24:6080-9.
30. Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, et al. Phase ii study of erlotinib in patients with malignant pleural mesothelioma: a southwest oncology group study. J Clin Oncol. 2007;25:2406-13.
31. Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R, et al. Pten expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg. 2008;33:502-6.
32. Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, et al. Activation of the pi3k-akt pathway in human malignant mesothelioma cells. Mol Med Rep. 2009;2:181-8.
33. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA. 1998;95:5246-50.
34. Salmena L, Carracedo A, Pandolfi PP. Tenets of pten tumor suppression. Cell. 2008;133:403-14.
35. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP. Pten and p27kip1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet. 2001;27:222-4.
36. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003;1:E59.
37. Gray IC, Stewart LM, Phillips SM, Hamilton JA, Gray NE, Watson GJ, et al. Mutation and expression analysis of the putative prostate tumour-suppressor gene pten. Br J Cancer. 1998;78:1296-300.
38. Mohiuddin I, Cao X, Ozvaran MK, Zumstein L, Chada S, Smythe WR. Phosphatase and tensin analog gene overexpression engenders cellular death in human malignant mesothelioma cells via inhibition of akt phosphorylation. Ann Surg Oncol. 2002;9:310-6.